Asian Pacific Journal of Cancer Prevention

  • 제16권13호
  • /
  • Pages.5365-5370
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer

  • Murray, Nigel P (Urology Service, Hospital de Carabineros de Chile, Nunoa, Faculty of Medicine) ;
  • Reyes, Eduardo (Urology Service, Hospital DIPRECA) ;
  • Fuentealba, Cynthia (Urology Service, Hospital de Carabineros de Chile, Nunoa, Faculty of Medicine) ;
  • Orellana, Nelson (Urology Service, Hospital de Carabineros de Chile, Nunoa, Faculty of Medicine) ;
  • Morales, Francisca (University Diego Portales) ;
  • Jacob, Omar (Urology Service, Hospital de Carabineros de Chile, Nunoa, Faculty of Medicine)
  • 발행 : 2015.08.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Combining risk factors for prostate cancer into a predictive tool may improve the detection of prostate cancer while decreasing the number of benign biopsies. We compare one such tool, age multiplied by prostate volume divided by total serum PSA (PSA-AV) with PSA density and detection of primary malignant circulating prostate cells (CPCs) in a Chilean prostate cancer screening program. The objectives were not only to determine the predictive values of each, but to determine the number of clinically significant cancers that would have been detected or missed. Materials and Methods: A prospective study was conducted of all men undergoing 12 core ultrasound guided prostate biopsy for suspicion of cancer attending the Hospital DIPRECA and Hospital de Carabineros de Chile. Total serum PSA was registered, prostate volumecalculated at the moment of biopsy, and an 8ml blood simple taken immediately before the biopsy procedure. Mononuclear cells were obtained from the blood simple using differential gel centrifugation and CPCs identified using immunocytchemistry with anti-PSA and anti-P504S. Biopsy results were classed as positive or negative for cancer and if positive the Gleason score, number of positive cores and percent infiltration recorded. Results: A total of 664 men participated, of whom 234 (35.2%) had cancer detected. They were older, had higher mean PSA, PSA density and lower PSA-AV. Detection of CPCs had high predictive score, sensitivity, sensibility and positive and negative predictive values, PSA-AV was not significantly different from PSA density in this population. The use of CPC detection avoided more biopsies and missed fewer significant cancers.Conclusions: In this screening population the use of CPC detection predicted the presence of clinically significant prostate cancer better than the other parameters. The high negative predictive value would allow men CPC negative to avoid biopsy but remain in follow up. The formula PSA-AV did not add to the predictive performance using PSA density.

키워드

참고문헌

  1. Anastasiadis E, van der Meulen J, Emberton M (2014). Hospital admissions after TRUS biopsy of the prostate in men diagnoses with prostate cancer: A database analysis in England. Int J Urol [Epub ahead of print].
  2. Beach R, Gown AM, Peralta-Venturina MN, et al (2002). P504S immunohistochemical detection in 405 prostatic specimens including 376 18-guage needle biopsies. Am J Surg Pathol, 26, 1588-96. https://doi.org/10.1097/00000478-200212000-00006
  3. Borgen E, Naume B, Nesland JM, et al (1999). Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy, 1, 377-88. https://doi.org/10.1080/0032472031000141283
  4. Campbell MF, Wein AJ, Kavoussi LR (2011). Campbell's Urology. V, Section II, chapter 3.
  5. Davis JW, Nakanishi H, Kumar VS, et al (2008). Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol, 179, 2187-91. https://doi.org/10.1016/j.juro.2008.01.102
  6. Draisma G, Etzioni R, Tsodikov A, et al (2009). Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context, J Natl Cancer Inst, 101, 374-88. https://doi.org/10.1093/jnci/djp001
  7. Epstein JI, Walsh PC, Carmichael M, et al (1994). Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA, 271, 368-74. https://doi.org/10.1001/jama.1994.03510290050036
  8. Eschwege P, Moutereau S, Droupy S, et al (2009). Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br J Cancer, 100, 608-10. https://doi.org/10.1038/sj.bjc.6604912
  9. Fizazi K, Morat L, Chauveinc L, et al (2007). High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol, 18, 518-21.
  10. Jiang J, Colli J, El-Galley R (2010). A simple method for estimating the optimum number of prostate biopsy cores to mantain high cancer detection rates while minimizing unnecessary biopsy sampling. J Endourol, 24, 143-7. https://doi.org/10.1089/end.2009.0285
  11. Lodeta B, Benko G, Car S, et al (2009). PSA density can help avoid unnecessary prostate biopsies at PSA range of 4-10ng/ml. Acta Clin Croat, 48, 153-5.
  12. Moreno JG, Croce CM, Fischer R, et al (1992). Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res, 52, 6110-2.
  13. Murray NP, Calaf GM, Badinez, et al (2010). P504S expressing circulating prostate cells as a marker for prostate cancer. Oncology Reports, 24, 687-92.
  14. Murray NP, Reyes E, Badinez L, et al (2013). Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications, J Oncol, [Epub ahead of print].
  15. Murray NP, Reyes E, Orellana N, et al (2013a). Cost benefit of the use of circulating prostate cells to detect prostate cancer. Arch Esp Urol, 66, 277-86.
  16. Murray NP, Reyes E, Fuentealba C, et al (2014) Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile. Asian Pac J Cancer Prev, 15, 9335-9. https://doi.org/10.7314/APJCP.2014.15.21.9335
  17. Murray NP, Reyes E, Fuentealba C, et al (2014a). Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer. J Oncol Volume, [Epub ahead of print].
  18. Murray NP, Reyes E, Orellana N, et al (2015). Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy. Asian Pac J Cancer Prev, 16, 601-6. https://doi.org/10.7314/APJCP.2015.16.2.601
  19. Patel S, Issa MM, El-Galley R (2012). Evaluation of novel formula of PSA, Age, Prostate Volume, and Race in Predicting positive prostate biopsy findings. Urol, 81, 602-6.
  20. Pavlakis K, Stravodimos K, Kapetanakis T, et al (2010). Evaluation of routine applications of P504S, 34${\beta}$E12 and p63 immunostaining on 250 prostate needle biopsy specimens. Int Urol Nephrol, 42, 325-30. https://doi.org/10.1007/s11255-009-9622-1
  21. Panteleakou Z, Lembessis P, Sourla A, et al (2009). Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med, 15, 101-14.
  22. Paterlini-Brechot P, Benali NL (2007). Circulating tumor cells (CTC) detection: Clinical impact and future directions, Cancer Letters, 253, 180-204. https://doi.org/10.1016/j.canlet.2006.12.014
  23. Raimondi C, Gradilone A, Naso G, et al (2011). Epithelialmesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treatment, 130, 449-55. https://doi.org/10.1007/s10549-011-1373-x
  24. Rubin MA, Zhou M, Dhanasekaran SM, et al (2001). alphamethylacyl Coenzyme-A racemase as a tissue biomarker for prostate cancer, JAMA, 287, 1662-70.
  25. Shariat SF, Karakiewicz PI, Roehrborn CG, et al (2008). An updated catalog of prostate cancer predictive tools. Cancer, 113, 3075-99. https://doi.org/10.1002/cncr.23908
  26. Smith DS, Humphrey PA, Catalona WJ (1997). The early detection of prostate carcinima with PSA. Cancer, 80, 1852-6. https://doi.org/10.1002/(SICI)1097-0142(19971101)80:9<1852::AID-CNCR25>3.0.CO;2-3
  27. Stott SL, Lee RJ, Nagrath S, et al (2010). Isolation and characterization of circulating tumor cell from patients with localized and metastatic prostate cancer. Sci Transl Med, 25, 25-30.
  28. van den Bergh RCN, Essink-Bot M, Roobol MJ, et al (2009). Anxiety and distress during active surveillance for early prostate cancer. Cancer, 115, 3868-78. https://doi.org/10.1002/cncr.24446
  29. Welch HG, Schwartz LM, Woloshin S (2005). PSA levels in the United States. Implications of various definitions for abnormal. J Natl Cancer Inst, 97, 1132-7. https://doi.org/10.1093/jnci/dji205
  30. Went PT, Lugli A, Meier S, et al (2004). Frequent EpCam protein expression in human carcinomas. Hum Pathol, 1, 122-8.
  31. Zhou M, Chinnaiyan AM, Lleer CG, et al (2002). Alphamethylacyl-CoA racemase: a novel tumor marker overexpressed in several human cancers and their precursor lesions. Am J Surg Pathol, 26, 926-31. https://doi.org/10.1097/00000478-200207000-00012